Spectral Med Inc (EDTXF)
Spectral Medical Inc. is a healthcare company focused on developing and commercializing products for septic shock treatment. Its commercial portfolio includes the Endotoxin Activity Assay, a rapid in-vitro diagnostic test designed to detect components of gram-negative bacterial cell walls, and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device intended to remove endotoxin from the bloodstream. The company also develops and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators used in research and development, as well as products manufactured for other diagnostic companies. Formerly known as Spectral Diagnostics Inc., the company adopted its current name in December 2014. Incorporated in 1991, Spectral Medical is headquartered in Toronto, Canada, and its common stock trades on OTC Markets under the ticker EDTX.F.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-EDTX.F
|
$0.65
|
-35.1% Downside
|
Overvalued
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
-10.9x
|
-5.8x
|
149.8x
|
292.2 M
|
312 M
|
5.1%
|
98.2%
|
-256.4
|
—
|
28.1%
|
